Journal Article (Review Article)

DZNE-2026-01046

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Consensus-based perspectives on integrating IPX203 into Parkinson's disease management.

Höglinger, G. (First author)DZNE* ; Buhmann, C. ; Ebersbach, G. ; Fabbri, M. ; Kägi, G. ; Pagonabarraga, J. ; Santos García, D. ; Tessitore, A. ; Tinazzi, M.

2026
Steinkopff [Darmstadt]

This record in other databases:    

Please use a persistent id in citations: doi:10.1007/s00415-026-14186-1

Abstract: Motor fluctuations are a common and burdensome complication of Parkinson's disease (PD) when the disease progresses, largely driven by the short half-life and variable absorption of immediate-release (IR) levodopa. IPX203 is a next-generation modified-release levodopa/carbidopa formulation that delivers rapid onset and sustained plasma levodopa concentrations through IR granules and extended-release pellets. Clinical studies have shown that IPX203 increases Good ON time (ON time without dyskinesia plus ON time with non-troublesome dyskinesia, equivalent to ON time without troublesome dyskinesia), reduces OFF time and improves motor symptom control compared with IR levodopa/carbidopa. In anticipation of the introduction of IPX203 in Europe, nine PD specialists convened to develop consensus recommendations for its use in clinical practice. Through a structured process incorporating predefined statements, voting and moderated discussion, the group reached high levels of agreement (88.9% to 100%) across seven topics. These included defining motor symptoms control, identifying patients most likely to benefit from IPX203, positioning of IPX203 within the treatment pathway, practical considerations for switching to IPX203 from current regimens and recommendations for monitoring and follow-up. The experts emphasised that IPX203 should be considered for patients with motor fluctuations insufficiently controlled on optimised oral levodopa therapy, before introduction of device-aided therapies. They highlighted the need for flexible dose adjustments, comprehensive patient and neurologist education and practical tools to support conversion to IPX203. This consensus insight provides practical guidance for integrating IPX203 into routine care of PD patients with motor fluctuations, aiming to increase mobility and reduce treatment burden for patients with PD.

Keyword(s): Humans (MeSH) ; Parkinson Disease: drug therapy (MeSH) ; Levodopa: therapeutic use (MeSH) ; Levodopa: administration & dosage (MeSH) ; Antiparkinson Agents: therapeutic use (MeSH) ; Antiparkinson Agents: administration & dosage (MeSH) ; Carbidopa: therapeutic use (MeSH) ; Carbidopa: administration & dosage (MeSH) ; Drug Combinations (MeSH) ; Disease Management (MeSH) ; Consensus (MeSH) ; Clinical consensus ; IPX203 ; Levodopa ; Modified-release formulation ; Motor fluctuation ; Parkinson disease ; Levodopa ; Antiparkinson Agents ; carbidopa, levodopa drug combination ; Carbidopa ; Drug Combinations

---

Contributing Institute(s):

1. Clinical Research (Munich) (Clinical Research (Munich))

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; DEAL Springer ; DEAL Springer ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---